---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-25-000009"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:42:15.519691+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B

## Summary
- Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.
- Full year 2024 net revenue $2.79B (+17% YoY); GAAP net loss $117M; adjusted EBITDA $627M (+12% YoY).
- All three segments (Affordable Medicines, AvKARE, Specialty) grew double-digits in FY24; CREXONT launched successfully.
- FY25 guidance: net revenue $3.0-$3.1B, adjusted EBITDA $650-$675M; net leverage reduced to 3.9x a year ahead of target.

## SEC filing metadata
- accession: 0001723128-25-000009
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000009/0001723128-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000009/amrx-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-25-000009
- JSON: https://secwatch.observer/filing/0001723128-25-000009.json
- Plain text: https://secwatch.observer/filing/0001723128-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.